SMT201700018B - Uso di sali di tungsteno (vi) per il trattamento della sterilità femminile in mammiferi non diabetici - Google Patents

Uso di sali di tungsteno (vi) per il trattamento della sterilità femminile in mammiferi non diabetici

Info

Publication number
SMT201700018B
SMT201700018B SM201700018T SM201700018T SMT201700018B SM T201700018 B SMT201700018 B SM T201700018B SM 201700018 T SM201700018 T SM 201700018T SM 201700018 T SM201700018 T SM 201700018T SM T201700018 B SMT201700018 B SM T201700018B
Authority
SM
San Marino
Prior art keywords
treatment
female sterility
tungsten salts
diabetic mammals
diabetic
Prior art date
Application number
SM201700018T
Other languages
English (en)
Italian (it)
Inventor
Almazan Ignacio Canals
Bugie Agnes Arbat
Original Assignee
Oxolife Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49999950&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SMT201700018(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Oxolife Sl filed Critical Oxolife Sl
Publication of SMT201700018B publication Critical patent/SMT201700018B/it

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/14Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Pregnancy & Childbirth (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Physiology (AREA)
SM201700018T 2013-01-22 2017-01-16 Uso di sali di tungsteno (vi) per il trattamento della sterilità femminile in mammiferi non diabetici SMT201700018B (it)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES201330071A ES2478790B1 (es) 2013-01-22 2013-01-22 Uso de sales de tungsteno (VI) para el tratamiento de la infertilidad femenina en mamíferos no diabéticos
PCT/EP2014/051141 WO2014114644A1 (en) 2013-01-22 2014-01-21 Use of tungsten (vi) salts for the treatment of female infertility in non-diabetic mammals

Publications (1)

Publication Number Publication Date
SMT201700018B true SMT201700018B (it) 2017-03-08

Family

ID=49999950

Family Applications (1)

Application Number Title Priority Date Filing Date
SM201700018T SMT201700018B (it) 2013-01-22 2017-01-16 Uso di sali di tungsteno (vi) per il trattamento della sterilità femminile in mammiferi non diabetici

Country Status (27)

Country Link
US (1) US9675638B2 (ru)
EP (1) EP2948156B1 (ru)
JP (1) JP6045721B2 (ru)
KR (1) KR102182563B1 (ru)
CN (1) CN105188721B (ru)
AU (1) AU2014209987B2 (ru)
BR (1) BR112015017483A2 (ru)
CA (1) CA2898953C (ru)
CL (1) CL2015002047A1 (ru)
CY (1) CY1118287T1 (ru)
DK (1) DK2948156T3 (ru)
ES (2) ES2478790B1 (ru)
HK (1) HK1217442A1 (ru)
HR (1) HRP20161611T1 (ru)
HU (1) HUE031910T2 (ru)
IL (1) IL240062B (ru)
LT (1) LT2948156T (ru)
MX (1) MX356851B (ru)
NZ (1) NZ710583A (ru)
PL (1) PL2948156T3 (ru)
PT (1) PT2948156T (ru)
RS (1) RS55418B1 (ru)
RU (1) RU2635507C2 (ru)
SG (1) SG11201505701WA (ru)
SI (1) SI2948156T1 (ru)
SM (1) SMT201700018B (ru)
WO (1) WO2014114644A1 (ru)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2639588B1 (es) * 2014-05-21 2018-09-06 Oxolife, S.L. Uso de una sal de tungsteno (VI) para favorecer la fertilidad y la reproducción normal en un mamífero hembra no diabético
ES2551828B1 (es) * 2014-05-21 2016-09-12 Oxolife S.L. Composiciones alimentarias que comprenden sales de tungsteno (VI)
CA2955914C (en) * 2014-07-21 2022-09-06 Ignacio Canals Almazan Tungsten (vi) salts for use thereof in the treatment of infertility, for favoring normal reproduction and fertility in a non-diabetic female mammal, as well as for improving the efficacy of assisted reproductive techniques
EP4368577A1 (en) * 2022-11-08 2024-05-15 Oxolife, S.L. Process for the preparation of tungsten (vi) salt hydrates

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4328134A (en) * 1980-05-06 1982-05-04 Schally Andrew Victor Anorexigenic peptides
ES2108642B1 (es) * 1995-07-26 1998-08-16 Quimica Farm Bayer Sa Composiciones de tungsteno (vi) para el tratamiento oral de la diabetes mellitus.
RU2141361C1 (ru) * 1998-03-12 1999-11-20 Пермская государственная медицинская академия Способ лечения ановуляторного бесплодия при ожирении
ES2187276B1 (es) * 2001-05-16 2004-08-01 Quimica Farmaceutica Bayer,S.A. Composiciones orales para el tratamiento de humanos obesos y no diabeticos.
AU2002368261A1 (en) * 2002-10-02 2004-04-23 Yeda Research And Development Co. Ltd. Long-acting gonadotropin-releasing hormone analogs and methods of use thereof
RU2270684C1 (ru) * 2005-01-20 2006-02-27 Анатолий Григорьевич Гриценко Лекарственный препарат "витасорб"
EP1972342A4 (en) * 2005-07-29 2011-01-12 Univ Barcelona PHARMACEUTICAL TREATED SALT (VI) COMPOSITIONS FOR THE TREATMENT OF NEURODEEGENERATIVE DISORDERS, IN PARTICULAR ALZHEIMER DISEASE AND SCHIZOPHRENIA
US20060100154A1 (en) * 2005-10-13 2006-05-11 Yeda Research And Development Co Long-acting gonadotropin-releasing hormone analogs and methods of use thereof

Also Published As

Publication number Publication date
MX356851B (es) 2018-06-18
EP2948156B1 (en) 2016-10-26
PT2948156T (pt) 2016-11-30
CA2898953A1 (en) 2014-07-31
KR20150130992A (ko) 2015-11-24
CL2015002047A1 (es) 2016-01-04
BR112015017483A2 (pt) 2017-07-11
AU2014209987B2 (en) 2016-09-01
ES2611776T3 (es) 2017-05-10
IL240062A0 (en) 2015-09-24
ES2478790A1 (es) 2014-07-22
US20150359820A1 (en) 2015-12-17
CA2898953C (en) 2018-01-02
NZ710583A (en) 2016-06-24
RU2015135578A (ru) 2017-03-02
CN105188721B (zh) 2017-10-31
WO2014114644A1 (en) 2014-07-31
DK2948156T3 (da) 2017-01-02
PL2948156T3 (pl) 2017-07-31
HUE031910T2 (en) 2017-08-28
KR102182563B1 (ko) 2020-11-25
ES2478790B1 (es) 2015-05-06
RS55418B1 (sr) 2017-04-28
HRP20161611T1 (hr) 2017-01-27
RU2635507C2 (ru) 2017-11-13
SI2948156T1 (sl) 2017-02-28
CY1118287T1 (el) 2017-06-28
LT2948156T (lt) 2016-12-27
HK1217442A1 (zh) 2017-01-13
US9675638B2 (en) 2017-06-13
CN105188721A (zh) 2015-12-23
SG11201505701WA (en) 2015-08-28
MX2015009364A (es) 2016-03-08
IL240062B (en) 2018-11-29
JP2016505057A (ja) 2016-02-18
JP6045721B2 (ja) 2016-12-14
AU2014209987A1 (en) 2016-01-21
EP2948156A1 (en) 2015-12-02

Similar Documents

Publication Publication Date Title
HUE061618T2 (hu) Vegyület szemrendellenességek kezelésére
EP3030323A4 (en) Kdm1a inhibitors for the treatment of disease
BR112015021732A2 (pt) dispositivo para uso terapêutico
SMT201500057B (it) Uso della biotina per il trattamento della sclerosi multipla
EP2967752A4 (en) MANUAL FRACTIONAL PIECE FOR DERMATOLOGICAL TREATMENTS
SMT201600054B (it) Uso di composti di 1h-indazolo-3-carbossammide come inibitori della glicogeno sintasi chinasi 3 beta
HK1220613A1 (zh) 具有遞送 蛋白治療眼部炎症
BR112014002830A2 (pt) fotossensibilizador para uso terapêutico
SMT201700018B (it) Uso di sali di tungsteno (vi) per il trattamento della sterilità femminile in mammiferi non diabetici
SMT201600395B (it) Derivati di pantotenato per il trattamento di disturbi neurologici
SMT201700004B (it) Uso di estratti di salvia haenkei in composizioni per antisenescenza
DK3003363T3 (da) Immunogen sammensætning til anvendelse i terapi
EP3733184C0 (en) PYRROLOPYRIMIDINE COMPOUNDS FOR USE IN THE TREATMENT OF CANCER
BR112017001384A2 (pt) composto para uso em tratamento anti-helmíntico
ITRM20120530A1 (it) Compounds for use in the treatment of parasitic diseases
SMT201700072B (it) Utilizzo del pidotimod per il trattamento della psoriasi
BR112014010432A2 (pt) uso médico
SMT201600416B (it) Uso di sali di 3-carbossi-n-etil-n,n-dimetilpropan-1-amminio nel trattamento di malattie cardiovascolari
BR112015004732A2 (pt) composto de piridinona para uso em terapia fotodinâmica
SMT201600363B (it) Modafinil per l’uso nel trattamento di cocainomani
SMT201700071B (it) Uso di pidotimod per il trattamento della dermatite atopica
DK2953577T3 (da) Engangsspytejektor til anvendelse i tandpleje
CO6801770A2 (es) Uso de secnidazol en el tratamiento de infecciones dentales
ITPN20130058A1 (it) Apparato perfezionato per il trattamento di biogas
FI20135228A (fi) Monikäyttötuoli